26 results
10-Q
2024 Q1
EX-10.3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
of those uploaded to the “Corporate Governance” section of the Company’s website.
5. D&O Insurance. The Company will maintain a policy for directors
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
, such as the corporate governance requirements or the minimum closing bid price requirement, NYSE American may take steps to delist our Common Stock … and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
, such as the corporate governance requirements or the minimum closing bid price requirement, NYSE American may take steps to delist our Common Stock … and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time
10-K
2023 FY
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
, such as the corporate governance requirements or the minimum closing bid price requirement, NYSE American may take steps to delist our Common Stock. Such a delisting … controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance
8-K
EX-3.2
CHRO
Chromocell Therapeutics Corp.
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
be in compliance, if elected as a director of the Corporation, and will comply with, all applicable publicly disclosed corporate governance, conflict
424B4
28oz7x ojl6
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
ozjd228 7tc9zw
20 Feb 24
Prospectus supplement with pricing info
5:28pm